Trastuzumab deruxtecan has durable activity in HER2-mutated NSCLC

External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site

Sep 18 / Springer Healthcare

Trastuzumab deruxtecan has durable activity in HER2-mutated NSCLC

Oncology Lung Cancer ESMO-2021

Description

Gilberto Lopes talks about why the results of the DESTINY-Lung01 trial of trastuzumab deruxtecan are so important for the subset of non-small-cell lung cancer patients with HER2 mutations, a population of unmet need.

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.